TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21962327

Group type: EXPERIMENTAL
Intervention: Device 1 (dedicated heart rate recording)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Device 2 (dedicated heart rate recording)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Device 3 (not specified)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Device 4 (not specified)
Number of subjects: 12
Study: 19478674

Group type: EXPERIMENTAL
Intervention: Lidocaine (33.0 microg kg(‐1) min(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 40
Study: 18028056

Group type: EXPERIMENTAL
Intervention: Snoezelen sensory adapted dental environment (SDE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional dental environment
Number of subjects: 19
Study: 19146603

Group type: EXPERIMENTAL
Intervention: Topical formulation containing 3.75% glycerol and 1.25% hydrolyzed jojoba esters (K-20W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycerol alone in a standard base skin care lotion
Number of subjects: 0
Study: 15380582

Group type: EXPERIMENTAL
Intervention: Single dose of electron beam radiotherapy (10 Gy)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham radiotherapy
Number of subjects: 106
Study: 11137759

Group type: EXPERIMENTAL
Intervention: CSF-total-tau
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CSF-phospho-tau
Number of subjects: 9
Study: 9355077

Group type: EXPERIMENTAL
Intervention: Fish oil therapy
Number of subjects: 0
Study: 8188016

Group type: EXPERIMENTAL
Intervention: FSH: LH ratio of 3:1
Number of subjects: 0

Group type: COMPARATOR
Intervention: FSH: LH ratio of 1:1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSH dominant gonadotrophins
Number of subjects: 0
Study: 3024959

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) administered at a daily dose of 0.5-1 mg intravenously or intramuscularly for 1-4 weeks.
Number of subjects: 64

Group type: COMPARATOR
Intervention: ACTH therapy
Number of subjects: 64
Study: 31539295

Group type: EXPERIMENTAL
Intervention: Panitumumab plus fluorouracil (FU), leucovorin (LV), and oxaliplatin (FOLFOX-4) induction followed by maintenance with panitumumab
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FU and LV
Number of subjects: 199

Group type: COMPARATOR
Intervention: Single-agent panitumumab
Number of subjects: 199
Study: 28384261

Group type: EXPERIMENTAL
Intervention: Miltefosine via caregiver Directly Observed Therapy (cDOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine antimoniate (MA)
Number of subjects: 0
Study: 27070526

Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral therapy (12 sessions)
Number of subjects: 169
Study: 25029875

Group type: EXPERIMENTAL
Intervention: 10 sessions of cardiac coherence biofeedback training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation programme only
Number of subjects: 31
Study: 21505845

Group type: EXPERIMENTAL
Intervention: Metabolic hyperventilation induced by 5 min of hypercapnic‐hyperoxic rebreathing (CO(2)‐R)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VH) of 3 min imposed by a metronome set at 25 cycles per min
Number of subjects: 8
Study: 19401621

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life measurement
Number of subjects: 0
Study: 18217461

Group type: EXPERIMENTAL
Intervention: Epidural clonidine before operation
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Epidural clonidine at the end of operation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 16297554

Group type: EXPERIMENTAL
Intervention: 4h of sleep per night (11 pm-3 am, N=22)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 8h of sleep per night (11 pm-7 am, N=18)
Number of subjects: 40
Study: 16579084

Group type: EXPERIMENTAL
Intervention: Chinese medicines for promoting blood circulation to remove blood stasis
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 9464200

Group type: EXPERIMENTAL
Intervention: Cocaine dependence with PTSD
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cocaine dependence without PTSD
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cocaine dependence (overall)
Number of subjects: 122
Study: 8584071

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) at a dosage higher than 100 mg/day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 6
Study: 2798949

Group type: EXPERIMENTAL
Intervention: Continuous, one‐to‐one professional support during labor
Number of subjects: 103
Study: 893875

Group type: EXPERIMENTAL
Intervention: Dry climate (25% relative humidity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Humid climate (90% relative humidity)
Number of subjects: 20
Study: 31136053

Group type: EXPERIMENTAL
Intervention: Synchronized Transcutaneous Electrical Acustimulation (STEA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synchronized Transcutaneous Electrical Acustimation (STEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 60
Study: 28828975

Group type: EXPERIMENTAL
Intervention: Customized patient-specific titanium mesh based on 3D printed model
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual intraoperative bending of titanium mesh
Number of subjects: 10
Study: 25224595

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (OC) combined with Caphosol()
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral cryotherapy (OC) only
Number of subjects: 40
Study: 23448434

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (starting dose, 0.4 μg·kg(‐1) ·h(‐1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Midazolam (starting dose, 0.1 mg·kg(‐1) ·h(‐1))
Number of subjects: 42
Study: 21091269

Group type: EXPERIMENTAL
Intervention: Clevidipine infusion starting at 2 mg/h, doubled every 3 min as needed to a maximum of 32 mg/h, continued for at least 18 h (96 h maximum).
Number of subjects: 126
Study: 19345309

Group type: EXPERIMENTAL
Intervention: WM + MPI
Number of subjects: 400

Group type: COMPARATOR
Intervention: WM
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: MPI
Number of subjects: 400
Study: 17258358

Group type: EXPERIMENTAL
Intervention: Pneumococcal protein D conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-immunized children)
Number of subjects: 0
Study: 15573657

Group type: EXPERIMENTAL
Intervention: 0.5‐mg/kg‐body weight midazolam mixed in strawberry syrup via the oral‐transmucosal route
Number of subjects: 40

Group type: COMPARATOR
Intervention: Syrup diluted with normal saline
Number of subjects: 40
Study: 11756595

Group type: EXPERIMENTAL
Intervention: IFNbeta-1b
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 9625287

Group type: EXPERIMENTAL
Intervention: Acarbose 25 mg t.i.d.
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg t.i.d.
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg t.i.d.
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 495
Study: 7841415

Group type: EXPERIMENTAL
Intervention: Antecedent behaviour-modifying 'prompting' strategy with earplugs and advice sheet
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Helmet modifications including standard earmuffs
Number of subjects: 41
Study: 3216720

Group type: EXPERIMENTAL
Intervention: RU 41740 (glycoprotein extract from Klebsiella pneumoniae)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31332093

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study: 28580833

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (500 mg, 3 times a day for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (starch supplement, 500 mg)
Number of subjects: 0
Study: 25939706

Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (50,000 IU retinyl palmitate)
Number of subjects: 4345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4345
Study: 23180572

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 82

Group type: COMPARATOR
Intervention: VBG
Number of subjects: 82
Study: 21787503

Group type: EXPERIMENTAL
Intervention: Micro-CT measurements
Number of subjects: 60

Group type: COMPARATOR
Intervention: Photographic measurements
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Repeated use of instruments (1st to 6th use)
Number of subjects: 60
Study: 19030909

Group type: EXPERIMENTAL
Intervention: Moderate dose (2 g) of n-3 PUFA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose (6.6 g) of n-3 PUFA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 60
Study: 16461040

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 3906

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3906
Study: 14605897

Group type: EXPERIMENTAL
Intervention: Non-invasive measures of respiratory muscle function
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Non-invasive measures of pulmonary function
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Maximum static respiratory pressures
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Maximum pressure-flow-power relationship
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Maximum incremental inspiratory muscle performance
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Within-subjects design
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Peak expiratory flow, maximum rate of pressure development, time constant of relaxation
Number of subjects: 46
Study: 11401423

Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline (PTX) with 100 mg carbamazepine (CBZ) at 22:00 h
Number of subjects: 2

Group type: COMPARATOR
Intervention: 100 mg carbamazepine (CBZ) alone at 22:00 h
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline (PTX) with 100 mg carbamazepine (CBZ) at 10:00 h
Number of subjects: 2

Group type: COMPARATOR
Intervention: 100 mg carbamazepine (CBZ) alone at 10:00 h
Number of subjects: 2
Study: 9563208

Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Sumatriptan (any dose)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg and 50 mg
Number of subjects: 1003
Study: 7517103

Group type: EXPERIMENTAL
Intervention: Individual/Direct therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Group/Consultation therapy
Number of subjects: 18
Study: 3279746

Group type: EXPERIMENTAL
Intervention: Amylose meal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Amylopectin meal
Number of subjects: 25
Study: 30705086

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic transforaminal discectomy (PETD)
Number of subjects: 3294

Group type: COMPARATOR
Intervention: Percutaneous endoscopic interlaminar discectomy (PEID)
Number of subjects: 3294

Group type: EXPERIMENTAL
Intervention: Both PETD and PEID
Number of subjects: 3294
Study: 28888268

Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg once daily
Number of subjects: 154

Group type: COMPARATOR
Intervention: Chlorthalidone 25mg once daily
Number of subjects: 154
Study: 25600720

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day (decreased by 100 mg every 5 days after the first 5 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Prednisone 75 mg/day (tapered off every 5 days after the first 5 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 97

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 97
Study: 24293498

Group type: EXPERIMENTAL
Intervention: Tailored screening protocol based on breast density (1 year for dense breasts, 2 years for lower density)
Number of subjects: 16596

Group type: COMPARATOR
Intervention: Usual care group (standard screening protocol)
Number of subjects: 16596
Study: 22179922

Group type: EXPERIMENTAL
Intervention: SBC Group (15 mcg clonidine added to bupivacaine 2.5 mg and sufentanil 5 mcg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SB Group (bupivacaine 2.5 mg and sufentanil 5 mcg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SBC Group
Number of subjects: 60

Group type: COMPARATOR
Intervention: SBC Group and SB Group
Number of subjects: 60
Study: 19194849

Group type: EXPERIMENTAL
Intervention: Re-integration training course
Number of subjects: 128

Group type: COMPARATOR
Intervention: Booster sessions
Number of subjects: 128
Study: 16794456

Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa beverage (446 mg of total flavanols)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-flavanol cocoa beverage (43 mg of total flavanols)
Number of subjects: 32
Study: 15545616

Group type: EXPERIMENTAL
Intervention: HMF-T (iron-fortified powdered human milk fortifier)
Number of subjects: 181

Group type: COMPARATOR
Intervention: HMF-C (commercially available human milk fortifier)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: HMF-T
Number of subjects: 181

Group type: COMPARATOR
Intervention: HMF-C
Number of subjects: 181
Study: 12867764

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) exercises via digital palpation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PFM exercises via biofeedback
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no exercises)
Number of subjects: 50
Study: 11074900

Group type: EXPERIMENTAL
Intervention: Oral fluconazole, 400 mg/d
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg twice daily
Number of subjects: 198
Study: 8656363

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Radial keratotomy (RK)
Number of subjects: 33
Study: 1506933

Group type: EXPERIMENTAL
Intervention: Prize drawing incentive (chance to win a dinner for two)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 844
Study: 4073078

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid (3.1 g every six hours via intravenous infusion)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Moxalactam (2.0 g every eight hours via intravenous infusion)
Number of subjects: 69
Study: 3314143

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30957444

Group type: EXPERIMENTAL
Intervention: Xingnao Kaiyin acupuncture combined with speech training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Basic therapy and speech rehabilitation exercises (control group)
Number of subjects: 68
Study: 28198565

Group type: EXPERIMENTAL
Intervention: Training nonnursing staff to provide feeding assistance (8-hour training curriculum)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 122
Study: 26010037

Group type: EXPERIMENTAL
Intervention: Epidural injections with corticosteroid plus lidocaine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Epidural injections with lidocaine alone
Number of subjects: 400
Study: 22211838

Group type: EXPERIMENTAL
Intervention: Post‐PaO2 > 70 mmHg
Number of subjects: 16

Group type: COMPARATOR
Intervention: PreOcc
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PostOcc
Number of subjects: 16
Study: 21672339

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone (4 mg once daily, orally)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 189
Study: 19454922

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 72
Study: 16433920

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes, total dose 1280/36 microg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Formoterol (9 microg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes, total dose 36 microg)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol and Formoterol (both treatments)
Number of subjects: 115
Study: 14973093

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg once daily) plus high-selenium baker's yeast (200 microg once daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Celecoxib (400 mg once daily) plus placebo
Number of subjects: 73
Study: 11334124

Group type: EXPERIMENTAL
Intervention: F/I 12.5/5 microg via Respimat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: F/I 25/10 microg via Respimat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: F/I 50/20 microg via Respimat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: F/I 100/40 microg via Respimat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: F/I 200/80 microg via Respimat
Number of subjects: 62

Group type: COMPARATOR
Intervention: F/I 50/20 microg via MDI
Number of subjects: 62

Group type: COMPARATOR
Intervention: F/I 100/40 microg via MDI
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9330146

Group type: EXPERIMENTAL
Intervention: Early mobilization starting at 3 days post-surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Late mobilization starting at 14 days post-surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 45
Study: 8175445

Group type: EXPERIMENTAL
Intervention: lonidamine (450 mg p.o. in three divided daily doses)
Number of subjects: 97

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: lonidamine
Number of subjects: 97
Study: 3364627

Group type: EXPERIMENTAL
Intervention: Budesonide (nasal spray, 400 micrograms/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (i.m. injection of 80 mg)
Number of subjects: 30
Study: 30860269

Group type: EXPERIMENTAL
Intervention: Flex office
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cell office
Number of subjects: 86
Study: 28361441

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioral therapy (T-CBT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 397
Study: 26930839

Group type: COMPARATOR
Intervention: Conventional instruction after discharge (Group A)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Continuing nursing care after discharge (Group B)
Number of subjects: 142
Study: 24073529

Group type: EXPERIMENTAL
Intervention: 500 microg-F/g with 0.25%CaGP (500 CaGP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1,100 microg-F/g (1,100) dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: 500 microg-F/g (500) dentifrice
Number of subjects: 10
Study: 22020609

Group type: EXPERIMENTAL
Intervention: Local retropharyngeal steroid (triamcinolone and morcellized collagen sponge)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Local retropharyngeal steroid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no steroid)
Number of subjects: 50
Study: 19225035

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) continued after 30 weeks
Number of subjects: 40
Study: 16802487

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 33

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 33
Study: 12929147

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics (PE) program
Number of subjects: 35
Study: 11402252

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diet
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study: 9209176

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet with increased iron content (27 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Very-low-energy diet with recommended dietary allowance of iron (18 mg/d)
Number of subjects: 0
Study: 8491505

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg/day for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3030678

Group type: EXPERIMENTAL
Intervention: 0.5 mg topically administered beclomethasone dipropionate (BDP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 5 mg betamethasone phosphate (BMT)
Number of subjects: 16
Study: 31552706

Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 sets × 10 repetitions of back squat, leg press, and leg extensions at 70% 1-RM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (30-min seated rest)
Number of subjects: 10
Study: 28742134

Group type: EXPERIMENTAL
Intervention: Compression device and a chitosan‐based pad
Number of subjects: 95

Group type: COMPARATOR
Intervention: Compression devices alone
Number of subjects: 95
Study: 25851955

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22618893

Group type: EXPERIMENTAL
Intervention: Iron-fortified fruit juice (F)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo fruit juice (P)
Number of subjects: 123
Study: 20723994

Group type: EXPERIMENTAL
Intervention: Clinical prediction score for visual acuity (VA) improvement
Number of subjects: 5512

Group type: EXPERIMENTAL
Intervention: Clinical prediction score for visual function index 14 (VF-14) improvement
Number of subjects: 5512

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves
Number of subjects: 5512
Study: 19246544

Group type: EXPERIMENTAL
Intervention: Verbal advice followed by an information sheet
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard verbal advice
Number of subjects: 700